论文部分内容阅读
为了评价新肿瘤标记CA125和CA19-9对消化器癌的诊断价值,作者检测健康人552例,胰腺癌29例,胆道癌24例,原发性肝癌40例,以及各种消化道非肿瘤性疾病患者血中CA125和CA19-9。CA125的正常值女性49岁以内为43u/ml,女性50岁以上及男性为32u/ml。正常妊娠三个月内者并不升高。结果各种疾病的阳性率如下:胰腺癌为63%,胆道癌为46%,原发性肝癌为40%,胃、食道及结肠癌为11-34%,肝硬化为35%(17例),慢活肝为10%(20例),其他急性、慢性胰腺炎、胆石症和溃疡者未见阳性。CA19-9以37u/ml以上为阳性,胰腺癌为
To evaluate the diagnostic value of the new tumor markers CA125 and CA19-9 in digestive cancer, the authors tested 552 healthy individuals, 29 pancreatic cancers, 24 biliary tract cancers, 40 primary liver cancers, and various non-neoplastic gastrointestinal tracts. Disease patients with CA125 and CA19-9 in blood. The normal value of CA125 was within the age of 49 years for women 43u/ml, for women over 50 years old and for men 32u/ml. No increase in normal pregnancy within three months. Results The positive rates of various diseases were as follows: 63% for pancreatic cancer, 46% for biliary tract cancer, 40% for primary liver cancer, 11-34% for stomach, esophagus, and colon cancer, and 35% for cirrhosis (17 cases). The rate of chronic livelihood was 10% (20 cases). Other acute and chronic pancreatitis, cholelithiasis, and ulceration were not positive. Positive for CA19-9 above 37u/ml, for pancreatic cancer